Clinical Trial Update: Efficacy, Safety, and Tolerability Study of Infliximab in Juvenile Spondyloarthropathies [Phase 2, Phase 3]

View source ↗

Summary

This update reports that infliximab was studied for efficacy, safety, and tolerability in juvenile spondyloarthritis in a Phase 2/3 trial that has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Spondyloarthritis
• Spondyloarthritis

Drugs mentioned

• Infliximab (infliximab)

Snippet

Sponsor: Hospital General de Mexico | Conditions: Spondylarthropathies | Phase 2, Phase 3 | Status: COMPLETED